Renalytix Plc

    Renalytix Plc

    NNASDAQ:RNLX
    - -
    USD
    - -
    - -
    Renalytix Plc
    NASDAQ:RNLX
    (Nasdaq Stock Market)

    Recent

    price

    - -

    P/E

    ratio

    - -

    div

    yld

    - -

    ROIC.AI

    2018
    2019
    2020
    2021
    2022
    2023
    2024
    TTM
    USD
    - -
    - -
    - -
    0.04
    0.08
    0.08
    0.04
    0.05
    Revenue per Share
    - -
    -2.27
    -0.33
    -0.87
    -1.24
    -1.11
    -0.62
    -0.56
    Basic EPS, GAAP
    - -
    -0.94
    -0.36
    -0.73
    -1.28
    -0.83
    -0.56
    -0.48
    Free Cash Flow per Basic Share
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Dividend per Share
    - -
    -2.29
    -1.77
    0.11
    -3.64
    -4.33
    -3.91
    -4.25
    Book Value per Share
    - -
    -0.52
    -0.04
    2.16
    0.46
    0.17
    -0.15
    -0.22
    Tangible Book Value per Share
    - -
    19
    30
    36
    36
    41
    54
    51
    Basic Weighted Avg Shares
    - -
    - -
    - -
    1
    3
    3
    2
    2
    Sales/Revenue/Turnover
    - -
    - -
    - -
    -2,187.19
    -1,790.67
    -1,240.7
    -1,261.9
    -1,051.83
    Operating Margin (%)
    - -
    - -
    - -
    2
    - -
    1
    - -
    - -
    Depreciation Expense
    - -
    -42
    -10
    -31
    -45
    -46
    -33
    -29
    Net Income, GAAP
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Effective Tax Rate (%)
    - -
    - -
    - -
    -2,079.81
    -1,524.44
    -1,340.2
    -1,461.6
    -1,219.26
    Profit Margin (%)
    -1
    8
    12
    69
    33
    11
    -5
    -9
    Working Capital
    - -
    - -
    - -
    - -
    8
    8
    4
    4
    LT Debt
    -1
    9
    16
    95
    31
    7
    -8
    -11
    Total Equity
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Return on Invested Capital (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Return on Capital (%)
    - -
    - -
    - -
    -158.83
    - -
    - -
    - -
    - -
    Return on Common Equity (%)

    Capital Structure

    USD

    •

    in mil. unless spec.
    Mar'24
    Jun'24
    Sep'25
    ST Debt
    5
    4
    4
    LT Borrowings
    5
    4
    4
    LT Finance Leases
    - -
    - -
    - -
    Preferred Equity and Hybrid Capital
    - -
    - -
    - -
    Shares Outstanding
    120
    154
    190
    Market Capitalization
    41
    11
    11

    Working Capital

    USD

    •

    in mil. unless spec.
    Mar'24
    Jun'24
    Sep'25
    Total Current Assets
    6
    6
    3
    Cash, Cash Equivalents & STI
    5
    5
    1
    Accounts Receivable, Net
    1
    1
    1
    Inventories
    - -
    - -
    - -
    Total Current Liabilities
    15
    11
    12
    Payables & Accruals
    - -
    - -
    - -
    ST Debt
    5
    4
    4
    Deferred Revenue
    - -
    - -
    - -

    Growth Rates

    USD

    •

    in mil. unless spec.

    (avg. rate of change)

    10 years
    5 years
    1 year
    Total Equity
    - -
    45.19%
    -212.73%
    Free Cash Flow
    - -
    28.93%
    -11.65%
    Net Income, GAAP
    - -
    31.67%
    -26.64%
    Sales/Revenue/Turnover
    - -
    - -
    -32.74%
    Total Cash Common Dividend
    - -
    - -
    - -

    Quarterly Revenue

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2023
    1
    1
    1
    1
    3
    2024
    - -
    1
    1
    1
    2
    2025
    1
    - -
    - -
    - -
    - -

    Quarterly Earnings Per Share

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2023
    -0.32
    -0.28
    -0.28
    - -
    -1.11
    2024
    -0.21
    - -
    -0.16
    - -
    -0.62
    2025
    -0.09
    - -
    - -
    - -
    - -

    Quarterly Dividends Per Share

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2023
    - -
    - -
    - -
    - -
    - -
    2024
    - -
    - -
    - -
    - -
    - -
    2025
    - -
    - -
    - -
    - -
    - -
    Similar Companies
    Business

    Company News

    Company News APIChatGPT

    • seekingalpha.com

      Renalytix Plc (RNLXY) Shareholder/Analyst Call Transcript

    • proactiveinvestors.co.uk

      Renalytix rises 7% as UBS holding grows and CEO buys shares

    • proactiveinvestors.co.uk

      Renalytix shares surge 19% as trading resumes after cash call

    • proactiveinvestors.co.uk

      Renalytix shares climb 24% as two-year kidney study data published

    • prnewswire.com

      Renalytix™ and Carna Health Partner to Solve Kidney Disease Crisis: Bridging the Existing Gap Between Population Screening and Precision Intervention

    • proactiveinvestors.co.uk

      Renalytix first half revenues rise, but cautions pipeline is taking longer to convert

    • proactiveinvestors.co.uk

      Renalytix shares fall 25% as revenues miss expectations

    • proactiveinvestors.co.uk

      Renalytix expands US footprint with three new clinical partnerships

    • defenseworld.net

      Renalytix (LON:RENX) Trading Down 1.7% – What’s Next?

    • proactiveinvestors.co.uk

      Renalytix reports £4m balance sheet boost as notes convert

    • proactiveinvestors.co.uk

      Renalytix upsized fundraise brings in £7m

    • proactiveinvestors.co.uk

      Renalytix to raise £4.5m to support US expansion

    • proactiveinvestors.co.uk

      Renalytix shares gain as billable test numbers set new company record

    • globenewswire.com

      Renalytix and Steno Diabetes Center Announce Precision Medicine Collaboration Marking First Expansion for KidneyIntelX Platform Beyond US

    • globenewswire.com

      Renalytix Submits Hearing Request to Nasdaq Hearings Panel in Regard to Staff Delisting Determination

    • globenewswire.com

      Medicare Issues Final Coverage Determination for kidneyintelX.dkd

    • seekingalpha.com

      Renalytix Plc (RNLX) Q3 2024 Earnings Call Transcript

    • globenewswire.com

      Renalytix Reports Financial Results for Third Quarter of Fiscal Year 2024

    • globenewswire.com

      Renalytix to Report Financial Results for Third Quarter Fiscal Year 2024 on May 15

    • globenewswire.com

      Renalytix Announces Financing with Expected Size of up to $4 Million